| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.008 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |